Action REVBU REVELATION BIOSCIENCES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Revelation Biosciences, Inc. Nasdaq

Actions

REVBU

US76135L2007

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Revelation Biosciences : NOTICE OF EXERCISE Form 8 K
PU
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
BU
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
BU
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
BU
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
BU
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
BU
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
BU
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
BU
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
BU
Revelation Biosciences : Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
PU
Thinking about buying stock in Meta Platforms, Ocular Therapeutix, Phathom Pharmaceuticals, Revelation Biosciences, or Sunworks?
PR
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
BU
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
BU
Thinking about buying stock in Guardion Health Sciences, Minim, Revelation Biosciences, Nyxoah, or Pixelworks?
PR
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
BU
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024
BU
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023
BU
Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies
BU
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference
BU
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
BU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action REVB
  4. Action REVBU
  5. Actualités Revelation Biosciences, Inc.
  6. Communiqués